Commercial success in building the next generation of therapeutic drugs begins with identifying and acquiring the best potential drug candidates. Once licensed, Calvert rapidly and efficiently advances those assets to preclinical or clinical proof of concept, and delivers a valuable therapeutic to a development partner or acquirer.

Our proven record of development and commercial success, driven by in-house expertise at each of these stages allows Calvert Research to leverage an integrated approach from the earliest phase of preclinical drug development. The result is a first-rate portfolio of therapeutic assets poised for commercial success and ready for acquisition.

Relationships are the foundation

Calvert has long-established relationships with the leaders in over 160 university technology transfer departments and thousands of researchers at these institutions. We have built strong and reputable relationships with key scientists and executives within the biopharma industry. These relationships enable us to secure, develop, and deliver top preclinical drug assets quickly.

Technology is primary

Our relationships with principal investigators, technology transfer officers, and biopharma leaders enable us to identify and process outstanding therapeutics, but novel technology is always our priority. Our senior scientists have world-class experience in the design and submission of clinical development programs to regulatory agencies, and work with each potential drug candidate to optimize design for commercial success.

In-house expertise is the enabler

Calvert Labs is well recognized in the CRO industry as a respected, high quality, and trusted partner of IND-enabling services. In the past five years alone, Calvert Labs has performed more than two thousand studies for over six hundred clients. Never in the forty year history of the company has a study been rejected by any international government health service regulatory body for design or conduct. Our scientific proficiency, experience, and proven track record in preclinical development are the key to adding value to our early-stage drug candidates.

Calvert Research carefully evaluates dozens of promising drug candidates each year. From this screening process, we identify a handful of compounds or technology platforms from which we make a full commitment to secure the best potential IP position. We swiftly progress each of our selected candidates through Calvert Labs until they are prepared for success in clinical development.